Jeffrey G. Lamothe's Insider Trades & SAST Disclosures
Jeffrey G. Lamothe's most recent trade in Aptevo Therapeutics Inc was a trade of 3 Common Stock done . Disclosure was reported to the exchange on March 2, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jeffrey G. Lamothe.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2025 | 3 | 34 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2025 | 3 | 4 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2025 | 2 | 36 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2025 | 2 | 0 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 272 | 1,166 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 272 | 0 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 42 | 41 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 42 | 894 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 12,825 | 12,825 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2024 | 5,500 | 33,837 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2024 | 5,500 | 11,000 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2024 | 3,667 | 37,504 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2024 | 3,667 | 3,667 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Lamothe Jeffrey G. | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2024 | 1,833 | 28,337 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Lamothe G. Jeffrey | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jan 2024 | 1,833 | 0 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 11,979 | 11,979 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 11,979 | 24,671 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 1,833 | 26,504 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 1,833 | 3,667 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 16,500 | 16,500 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 3,666 | 12,692 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | EVP, COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 3,666 | 7,334 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2023 | 1,834 | 1,833 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2023 | 1,834 | 9,026 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2022 | 23,958 | 23,958 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2022 | 5,500 | 5,500 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Aug 2022 | 5,500 | 5,500 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 11,000 | 11,000 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2022 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2022 | 1,833 | 7,192 (0%) | 0% | - | Common Stock | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2022 | 1,833 | 3,667 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2021 | 5,500 | 5,500 | - | - | Restricted Stock Unit | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2020 | 7,380 | 7,380 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 4,814 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 4,814 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 3,128 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 2,695 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 2,407 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 2,407 | 0 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2020 | 2,140 | 2,140 | - | - | Stock Option (right to buy) | |
| Aptevo Therapeutics Inc | Jeffrey G. Lamothe | SVP and CFO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jul 2020 | 1,928 | 0 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges